MacroGenics Statistics
Total Valuation
MacroGenics has a market cap or net worth of $205.55 million. The enterprise value is $39.60 million.
Important Dates
The last earnings date was Tuesday, November 5, 2024, after market close.
| Earnings Date | Nov 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MacroGenics has 62.76 million shares outstanding. The number of shares has increased by 0.77% in one year.
| Current Share Class | 62.76M |
| Shares Outstanding | 62.76M |
| Shares Change (YoY) | +0.77% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 2.72% |
| Owned by Institutions (%) | 73.86% |
| Float | 51.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.45 |
| Forward PS | 7.69 |
| PB Ratio | 1.71 |
| P/TBV Ratio | 1.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.28 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.75, with a Debt / Equity ratio of 0.28.
| Current Ratio | 3.75 |
| Quick Ratio | 3.53 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -94.03 |
Financial Efficiency
Return on equity (ROE) is -62.17% and return on invested capital (ROIC) is -35.02%.
| Return on Equity (ROE) | -62.17% |
| Return on Assets (ROA) | -22.15% |
| Return on Capital (ROIC) | -35.02% |
| Revenue Per Employee | $416,900 |
| Profits Per Employee | -$287,956 |
| Employee Count | 339 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 89.39 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.47% in the last 52 weeks. The beta is 2.08, so MacroGenics's price volatility has been higher than the market average.
| Beta (5Y) | 2.08 |
| 52-Week Price Change | -57.47% |
| 50-Day Moving Average | 3.65 |
| 200-Day Moving Average | 8.03 |
| Relative Strength Index (RSI) | 37.44 |
| Average Volume (20 Days) | 749,569 |
Short Selling Information
The latest short interest is 5.46 million, so 8.70% of the outstanding shares have been sold short.
| Short Interest | 5.46M |
| Short Previous Month | 5.37M |
| Short % of Shares Out | 8.70% |
| Short % of Float | 10.65% |
| Short Ratio (days to cover) | 10.07 |
Income Statement
In the last 12 months, MacroGenics had revenue of $141.33 million and -$97.62 million in losses. Loss per share was -$1.56.
| Revenue | 141.33M |
| Gross Profit | -51.30M |
| Operating Income | -107.10M |
| Pretax Income | -136.37M |
| Net Income | -97.62M |
| EBITDA | -99.71M |
| EBIT | -107.10M |
| Loss Per Share | -$1.56 |
Full Income StatementBalance Sheet
The company has $200.36 million in cash and $34.10 million in debt, giving a net cash position of $166.26 million or $2.65 per share.
| Cash & Cash Equivalents | 200.36M |
| Total Debt | 34.10M |
| Net Cash | 166.26M |
| Net Cash Per Share | $2.65 |
| Equity (Book Value) | 120.07M |
| Book Value Per Share | 1.91 |
| Working Capital | 162.89M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$58.00 million and capital expenditures -$3.71 million, giving a free cash flow of -$61.71 million.
| Operating Cash Flow | -58.00M |
| Capital Expenditures | -3.71M |
| Free Cash Flow | -61.71M |
| FCF Per Share | -$0.98 |
Full Cash Flow StatementMargins
Gross margin is -36.30%, with operating and profit margins of -75.78% and -69.07%.
| Gross Margin | -36.30% |
| Operating Margin | -75.78% |
| Pretax Margin | -69.07% |
| Profit Margin | -69.07% |
| EBITDA Margin | -70.55% |
| EBIT Margin | -75.78% |
| FCF Margin | -382.60% |
Dividends & Yields
MacroGenics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.77% |
| Shareholder Yield | -0.77% |
| Earnings Yield | -47.42% |
| FCF Yield | -29.98% |
Analyst Forecast
The average price target for MacroGenics is $8.57, which is 161.68% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.57 |
| Price Target Difference | 161.68% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 22.81% |
| EPS Growth Forecast (5Y) | 59.92% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MacroGenics has an Altman Z-Score of -3.88 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.88 |
| Piotroski F-Score | 3 |